Contact US

NeoMed Awarded US Patent for ENFit® Low Dose Tip Syringe

Woodstock, GA –  NeoMed, an enteral feeding and medica­tion delivery solu­tion leader, announced today it has received intel­lec­tual prop­erty protec­tion for its ENFit® Low Dose Tip Syringe in the form of US Patent No. 10,420,709, enti­tled “Dosing Control Coupling For Enteral Fluid Transfer.” NeoMed recently recog­nized inven­tors Ben Davis, Aaron Ingram, Duane Webb, and Mariann Cary for pioneering this inno­v­a­tive device.

This new patent, which was awarded to NeoMed by the United States Patent and Trademark Office on September 24, 2019, serves to further protect NeoMed’s inno­va­tion covering the ENFit Low Dose Tip Syringe, which has become the accepted solu­tion throughout the medical device industry and the health­care commu­nity for low volume dose accu­racy with ENFit syringes.  Also protecting NeoMed’s ENFit Low Dose Tip Syringe tech­nology, NeoMed received granted UK Patent No. 2,546,462 and has numerous other patent appli­ca­tions pending around the world.

“Clinicians expect accu­rate low volume dosing, and that’s exactly what the ENFit Low Dose Tip Syringe provides. The successful issuance of this patent rein­forces NeoMed’s ongoing commit­ment to improving patient safety and outcomes through inno­va­tion and product design. The safety of the fragile, prema­ture babies we serve is the corner­stone of our product designs, which is why NeoMed has made the ENFit Low Dose Tip Syringe tech­nology avail­able through no-cost licensing agree­ments to numerous enti­ties throughout the world,” stated NeoMed’s Vice President of Engineering and Product Development, Ben Davis.

“Low Dose Tip Syringes are neces­sary for successful ENFit conver­sions. As such, we believe that this patented tech­nology will help elim­i­nate ENFit imple­men­ta­tion barriers and boost global ENFit adop­tion. NeoMed is proud to exceed industry recom­men­da­tions by providing the NeoConnect® Low Dose Tip Syringes in sizes that range from 0.5 mL to 6 mL,” remarked NeoMed President, Aaron Ingram.

NeoMed’s global patent port­folio includes 66 granted patents and 87 pending patent appli­ca­tions in juris­dic­tions throughout the world.

About NeoMed, Inc.

Founded in 2007, NeoMed develops inno­v­a­tive enteral collec­tion and delivery prod­ucts supporting the special­ized feeding and medica­tion dosing needs of the low birth weight, neonatal, and pedi­atric patients. NeoMed is committed to improve patient outcomes through product designs that meet safety, clin­ical, and regu­la­tory guide­lines while supporting cost-containment objec­tives. For more infor­ma­tion, visit neomedinc.com.

From left: Aaron Ingram, Ben Davis, Duane Webb and Mariann Cary